

Attorney Docket No. O/1999.475 US

Please add the following subject heading on page 3, line 21:


--Detailed Description of the Invention--

In the Claims


Please cancel claims 1-6 without prejudice or disclaimer of the subject matter contained therein.

Please amend the claims as follows:


7. (Amended) A cyclophane compound having formula A




wherein R is



formula B



Attorney Docket No. O/1999.475 US

A Cont
wherein X is

; or a pharmaceutical acceptable salt thereof.

A2
10. (Amended) The kit according to claim 9, wherein the neuromuscular blocking agent is rocuronium and the chemical chelator is γ -cyclodextrin or a derivative thereof.

11. (Amended) A method for reversal of drug-induced neuromuscular block in a patient, comprising:

parentally administering to said patient an effective amount of a chemical chelator capable of forming a guest-host complex with the drug inducing the neuromuscular block in a patient.

Please add the following claims:

A3
--12. The method according to claim 11, wherein the drug inducing the neuromuscular block in the patient is rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, (cis)atracurium, tubocurarine or suxamethonium.

A3cont

Attorney Docket No. 0/1999.475 US

13. The method according to claim 11, wherein the chemical chelator is selected from the group consisting of cyclic oligosaccharides and cyclophanes.

14. The method according to claim 11, wherein the drug inducing neuromuscular block in a patient is rocuronium and the chemical chelator is γ -cyclodextrin or a derivative thereof.

15. A pharmaceutical composition, comprising:
a chemical chelator capable of reversing a drug-induced neuromuscular block, and
and a pharmaceutically acceptable excipient.

16. The pharmaceutical composition according to claim 15, wherein the chelator is selected from the group consisting of cyclic oligosaccharides and cyclophanes.


17. The pharmaceutical composition according to claim 16, wherein the cyclic oligosaccharide is a cyclodextrin or a derivative thereof.

18. The pharmaceutical composition according to claim 17, wherein the cyclodextrin is γ -cyclodextrin or a derivative thereof.


Attorney Docket No. O/1999.475 US

A³Cot.

19. The pharmaceutical composition according to claim 16,
wherein the cyclophane is represented by formula A




wherein R is




and n is 1-5; or

formula B



wherein X is



--